3D-Printed fork handles could help dementia patients eat on their own
NCT ID NCT07087574
First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This study tests whether custom 3D-printed cutlery handles can help people with neurodegenerative diseases eat more independently. 75 patients in rehabilitation care will try handles in different sizes, designed to fit their grip. Researchers will measure changes in eating ability and food intake over three days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 3D-printed ergonomic cutlery handles
- What this could lead to
- If successful, this could offer a low-cost, personalized tool to help patients with neurodegenerative diseases eat more independently and improve their nutritional intake.
- What could go wrong
- This is a small, early-stage study (75 participants) testing a device over just a few days. Results may not apply to all patients, and the benefit may be limited to short-term use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURO-DEGENERATIVE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Georges Clemenceau
RECRUITINGLa Garde, Var, 83130, France
-
SSR Pierre Chevalier
RECRUITINGHyères, Var, 83400, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the Brain's response to deep brain stimulation?
- Could sharing lived experiences ease the burden of dementia care?
- Scientists watch brain activity as stroke survivors walk and think
- One million volunteers join quest to decode aging
- Italian swallowing assessment tool validated for neurodegenerative patients
- New ALS drug trial aims to tame inflammation